GPT and metabolic dysfunction-associated steatotic liver disease: We examined the association of prevalent and incident CVD with an array of biomarkers, including those measuring non-specific liver injury (plasma liver enzymes), steatosis (ultrasound), steatohepatitis (cytokeratin-18 [CK18] [8]), surrogate of advanced portal hypertension (platelet count), and liver fibrosis (aspartate to platelet ratio index [APRI] [9], aspartate aminotransferase [AST] to alanine aminotransferase [ALT] ratio, fibrosis-4 score [FIB4] [10], enhanced liver fibrosis panel [ELF] [11] and NAFLD fibrosis score [NFS] [12]).